Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27972)	2/7/1999 1:08:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< However, it was subsequently observed to have an effect on ER- breast cancer also. >> First, thanks for your response. But...... when you say that Tamoxifen was found to have other uses, wasn't that up to the company to find, and not at the FDA's behest? Isn't the FDA a little unfair requesting that Ligand test ONTAK for other uses, if Ligand has other priorities, such as their Targretin NDA's, and wouldn't ordinarily pursue other uses for ONTAK at this time. TIA, Bob